Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):190–196. doi: 10.1097/QAI.0b013e3182167516

Figure 3.

Figure 3

A) Proportion of subjects in each group who had a low (≤1:3200) IgG reciprocal endpoint titer to KEX1 at each visit. Visits 1, 2, and 3 are prior to the first AIDS-defining illness, and visits 4, 5, and 6 are after the first AIDS-defining illness. B) Proportion of subjects in each group who had a high (>1:3200) IgG antibody titer to KEX1 before (Visit 1) and after (Visit 6) AIDS-defining illness. No PcP = group that had an illness other than PcP for their first AIDS-defining illness. PcP = group that had PcP as their first AIDS-defining illness.